GRP78, a
molecular chaperone with critical endoplasmic reticulum functions, is aberrantly expressed on the surface of
cancer cells, including prostate and
melanoma. Here it functions as a pro-proliferative and anti-apoptotic signaling receptor via NH(2)-terminal domain
ligation. Auto-
antibodies to this domain may appear in
cancer patient serum where they are a poor prognostic
indicator. Conversely,
GRP78 COOH-terminal domain
ligation is pro-apoptotic and anti-proliferative. There is no method to disrupt cell-surface
GRP78 without compromising the total
GRP78 pool, making it difficult to study cell-surface
GRP78 function. We studied six cell lines representing three
cancer types. One cell line per group expresses high levels of cell-surface
GRP78, and the other expresses low levels (human
hepatoma: Hep3B and HepG2; human
prostate cancer: PC3 and 1-LN; murine
melanoma: B16F0 and B16F1). We investigated the effect of Escherichia coli subtilase cytoxin catalytic subunit (SubA) on
GRP78. We report that SubA specifically cleaves cell-surface
GRP78 on HepG2, 1-LN, and B16F1 cells without affecting intracellular
GRP78. B16F0 cells (
GRP78(low)) have lower amounts of cleaved cell-surface
GRP78. SubA has no effect on Hep3B and PC3 cells. The predicted 28-kDa
GRP78 COOH-terminal fragment is released into the culture medium by SubA treatment, and COOH-terminal domain signal transduction is abrogated, whereas pro-proliferative signaling mediated through NH(2)-terminal domain
ligation is unaffected. These experiments clarify cell-surface
GRP78 topology and demonstrate that the COOH-terminal domain is necessary for pro-apoptotic signal transduction occurring upon COOH-terminal antibody
ligation. SubA is a powerful tool to specifically probe the functions of cell-surface
GRP78.